Literature DB >> 10744367

In vitro activity of quinupristin/dalfopristin (Synercid, RP 59500) against Legionella spp.

P H Edelstein1, M A Edelstein.   

Abstract

The activities of quinupristin/dalfopristin (Synercid), erythromycin and azithromycin against 22 Legionella spp. isolates were measured by a microbroth dilution method. The MICs that inhibited 90% of strains tested were 0.5, 0.35, and 0.5 microg/mL for quinupristin/dalfopristin, erythromycin, and azithromycin, respectively. Quinupristin/dalfopristin was only partially active against intracellular L. pneumophila at high (2 microg/mL), but not low (1 microg/mL) concentration. Activity of the drug in a guinea pig model of Legionnaires' disease could not be accurately determined because of drug toxicity for the guinea pig, although there was evidence that the drug has in vivo activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744367     DOI: 10.1016/s0732-8893(99)00107-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

1.  In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; F Higa; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

2.  In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; T Shinzato; E Doyle; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii.

Authors:  P D Walzer; A Ashbaugh; M Collins; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

4.  Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia.

Authors:  Paul H Edelstein; William J Weiss; Martha A C Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.